BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.